Systemic Innate Immune Responses in Secondary Syphilis

二期梅毒的全身先天免疫反应

基本信息

  • 批准号:
    7342736
  • 负责人:
  • 金额:
    $ 3.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-01-01 至 2010-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Venereal syphilis is a sexually transmitted disease caused by the spirochetal pathogen, Treponema pallidum. The disease remains uncontrolled, particularly in resource-scarce regions where testing, treatment and proper follow-up are not always accessible. Syphilis is characterized by the appearance of a local ulcer at the site of initial infection to an array of chronic systemic inflammatory manifestations that when left untreated, can cause severe complications and even death. The inability to culture the bacterium has hampered efforts to fully understand its pathogenesis, particularly why the spirochete is able to evade the immune system. The research proposed here is thus designed to better characterize the nature this immune response as it occurs in human syphilis. The systemic cellular innate immune response in secondary syphilis patients will be the focus of the current proposal. We hypothesize that in secondary syphilis, the presence of T. pallidum in the blood directly activates circulating monocytes and dendritic cells. To do so, in Specific Aim 1 we will first confirm that spirochetal DNA is present in blood from secondary syphilis patients using a novel Real Time Quantitative PCR method and in Specific Aim 2 we will characterize T. pallidum driven immune responses in circulating monocytes and dendritic cells by using multiparameter four color flow cytometry and `real time' PCR (RT-PCR) to quantify their pro- inflammatory cytokine gene expression signals. Complementary ex vivo studies, are structured to identify the effect of the bacterium on specific components of innate and adaptive immune cells. From these two parallel lines of research, we will obtain a more mechanistic understanding of the pathogenesis of syphilis, which can be further developed along cellular and molecular lines and ultimately facilitate development of a vaccine. In concert with the Fogarty International Center's mission to reduce health disparities amongst nations, the planned activities will also: (1) support collaborative syphilis immunobiology research between the USPI and the FC in Cali, Colombia; (2) strengthen the foreign institute's (CIDEIM), research capabilities and technical base; (3) foster sustained and productive research between two US based institutions (UCHC and CCMC) and CIDEIM; and (4) provide needed epidemiological data about venereal syphilis for that region of Colombia.
描述(由申请人提供):性病梅毒是一种由螺旋体病原体梅毒螺旋体引起的性传播疾病。这种疾病仍然得不到控制,特别是在资源匮乏的地区,那里并不总是能够得到检测、治疗和适当的后续行动。梅毒的特征是在初始感染部位出现局部溃疡,并出现一系列慢性全身性炎症表现,如果不进行治疗,可能导致严重的并发症甚至死亡。无法培养这种细菌阻碍了充分了解其发病机制的努力,特别是为什么螺旋体能够逃避免疫系统。因此,这里提出的研究旨在更好地描述这种免疫反应在人类梅毒中发生的性质。二期梅毒患者的系统性细胞天然免疫反应将是目前建议的重点。我们推测,在二期梅毒中,T。血液中的苍白球直接激活循环单核细胞和树突细胞。为此,在具体目标1中,我们将首先使用新的真实的时间定量PCR方法确认螺旋体DNA存在于来自二期梅毒患者的血液中,并且在具体目标2中,我们将表征T。通过使用多参数四色流式细胞术和“真实的时间”PCR(RT-PCR)定量它们的促炎细胞因子基因表达信号,在循环单核细胞和树突细胞中检测苍白球驱动的免疫应答。互补的离体研究被构造成鉴定细菌对先天性和适应性免疫细胞的特定组分的影响。从这两条平行的研究路线中,我们将获得对梅毒发病机制的更机理的理解,这可以进一步沿着细胞和分子路线发展,并最终促进疫苗的开发。为配合福格蒂国际中心缩小各国之间健康差距的使命,计划开展的活动还将:(1)支持USPI和哥伦比亚卡利FC之间的梅毒免疫生物学合作研究;(2)加强外国研究所(CIDEIM)的研究能力和技术基础;(3)促进两个美国机构(UCHC和CCMC)和CIDEIM之间的持续和富有成效的研究;(4)提供哥伦比亚该地区所需的性病梅毒流行病学数据。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Juan C Salazar其他文献

Juan C Salazar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Juan C Salazar', 18)}}的其他基金

Global sequence and surface antigenic diversity of Treponema pallidum outer membrane proteins
梅毒螺旋体外膜蛋白的整体序列和表面抗原多样性
  • 批准号:
    10683549
  • 财政年份:
    2019
  • 资助金额:
    $ 3.94万
  • 项目类别:
Global sequence and surface antigenic diversity of Treponema pallidum outer membrane proteins
梅毒螺旋体外膜蛋白的整体序列和表面抗原多样性
  • 批准号:
    10618191
  • 财政年份:
    2019
  • 资助金额:
    $ 3.94万
  • 项目类别:
Global sequence and surface antigenic diversity of Treponema pallidum outer membrane proteins
梅毒螺旋体外膜蛋白的整体序列和表面抗原多样性
  • 批准号:
    10399447
  • 财政年份:
    2019
  • 资助金额:
    $ 3.94万
  • 项目类别:
Phagosomal Signals Shape Inflammatory Responses to B. Burgdorferi
吞噬体信号塑造对伯氏疏螺旋体的炎症反应
  • 批准号:
    8186600
  • 财政年份:
    2011
  • 资助金额:
    $ 3.94万
  • 项目类别:
Phagosomal Signals Shape Inflammatory Responses to B. Burgdorferi
吞噬体信号塑造对伯氏疏螺旋体的炎症反应
  • 批准号:
    8685101
  • 财政年份:
    2011
  • 资助金额:
    $ 3.94万
  • 项目类别:
Phagosomal Signals Shape Inflammatory Responses to B. Burgdorferi
吞噬体信号塑造对伯氏疏螺旋体的炎症反应
  • 批准号:
    8485531
  • 财政年份:
    2011
  • 资助金额:
    $ 3.94万
  • 项目类别:
Phagosomal Signals Shape Inflammatory Responses to B. Burgdorferi
吞噬体信号塑造对伯氏疏螺旋体的炎症反应
  • 批准号:
    8298155
  • 财政年份:
    2011
  • 资助金额:
    $ 3.94万
  • 项目类别:
Phagosomal Signals Shape Inflammatory Responses to Borrelia Burgdorferi
吞噬体信号塑造对伯氏疏螺旋体的炎症反应
  • 批准号:
    8145100
  • 财政年份:
    2010
  • 资助金额:
    $ 3.94万
  • 项目类别:
Systemic Innate Immune Responses in Secondary Syphilis
二期梅毒的全身先天免疫反应
  • 批准号:
    7547764
  • 财政年份:
    2008
  • 资助金额:
    $ 3.94万
  • 项目类别:
Systemic Innate Immune Responses in Secondary Syphilis
二期梅毒的全身先天免疫反应
  • 批准号:
    7753673
  • 财政年份:
    2008
  • 资助金额:
    $ 3.94万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 3.94万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 3.94万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 3.94万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.94万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 3.94万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 3.94万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 3.94万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 3.94万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 3.94万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 3.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了